Note 19 - Segment and Geographic Information

12 Months Ended

May 31, 2014

Segment Reporting [Abstract]

Segment Reporting Disclosure [Text Block]

19. SEGMENT AND GEOGRAPHIC INFORMATION

The Company determines operating segments in accordance with its internal operating structure, which is organized based upon product groups. Each segment is separately managed and is evaluated primarily upon operating results. The Company has two operating segments, the Transfusion segment and the Transplant & Molecular segment, which have been aggregated into one reportable segment.

The Company manufactures and markets a complete line of diagnostics products and automated systems used primarily by hospitals, donor centers and reference laboratories in a number of tests performed to detect and identify certain properties of human blood and human tissue to ensure the most compatible match between patient and donor. These tests are performed for the purpose of blood transfusion, pre-transplant human leukocyte antigen (HLA) typing and screening processes as well as post-transplant patient monitoring to aid in the identification of graft rejection.

The Company operates in various geographies. These geographic markets are comprised of the United States, Europe, Canada and other international markets. Major international markets include the BRIC region (countries of Brazil, Russia, India and China), the Asia Pacific region, and Mexico. These products are marketed globally, both directly to the end user and through established distributors.

Accounting policies for segments are the same as those described in the summary of significant accounting policies.

The following segment data is presented for the twelve months ended May 31, 2014, May 31, 2013, and May 31, 2012 (separated into Predecessor and Successor periods) as follows (in thousands):

					Successor		Predecessor
					August 20, 2011		June 1, 2011
	Year Ended				through		through
	May 31, 2014		May 31, 2013		May 31, 2012		August 19, 2011
Net sales by product group:
Transfusion	$	330,547		330,931		257,046		73,632
Transplant & Molecular		57,509		16,857		4,768		1,278
Total	$	388,056		347,788		261,814		74,910

Following is a summary of enterprise-wide information (in thousands):

					Successor		Predecessor
					August 20, 2011		June 1, 2011
	Year Ended				through		through
	May 31, 2014		May 31, 2013		May 31, 2012		August 19, 2011
Net sales to customers by geography are as follows:
United States	$	239,204		229,944		173,918		50,988
Europe (A)		79,219		63,643		49,486		14,180
Canada		19,127		19,985		14,349		3,907
Other		50,506		34,216		24,061		5,835
Total	$	388,056		347,788		261,814		74,910

Net sales are attributed to individual countries based on the customer's country of origin at the time of the sale and where the  Company has an operating entity.

	As of May 31
	2014		2013
Long-lived assets (excluding goodwill and intangibles) by geography:
United States	$	54,066		57,184
Europe (B)		15,725		13,399
Canada		4,517		4,511
Other (C)		2,003		1,287
Total	$	76,311		76,381

	As of May 31
	2014		2013
Concentration of net assets by geography:
United States	$	299,948		485,968
Europe		123,095		114,740
Canada		32,802		32,910
Other (C)		12,771		11,088
Total	$	468,616		644,706

(A) – Net sales to any individual country within Europe were not material to the Company’s consolidated net sales.

(B) – Long-lived assets located in any individual country within Europe were not material to the Company's consolidated long-lived assets.

(C) – Primarily Japan and India.

Sales to an individual customer did not exceed more than 10% of our annual net sales during any of the years ended May 31, 2014, May 31, 2013, or the Successor and Predecessor fiscal 2012 periods.